SmartTRAK is excited to be attending #SNIS - Society of Neuro Interventional Surgery's 15th annual meeting on July 23-26 at the Hilton San Francisco Union Square, in San Francisco, California.SmartTRAK will be represented by Anne Staylor, Managing Editor, Business Intelligence and Senior Director, Advanced Technologies and Christopher McCarthy, Vice President Corporate Accounts, Orthopedics and Neuro. Please contact us if you would like a meeting.
In May 2017, Nevro CEO Rami Elghandour chatted with Anne Staylor, BioMedGPS Managing Editor/Neuro Analyst to discuss dynamics in the global spinal cord stimulation (SCS) market, including trends, drivers, challenges, competition, and opportunity that would influence the Company’s growth.
A fascinating read then, that now has us appraising a year later if Elghandour's expansion predictions came to pass. Is Nevro still the one to beat as the top leader in the neuromodulation field?
Scott Drees, CEO of Nuvectra Corporation, discusses the Company’s challenges and opportunities in 2017, strategies for driving growth and market penetration in neuromodulation, and the Company’s key priorities for 2018 in an interview with SmartTRAK at the North American Neuromodulation Society Annual Meeting held Jan. 11-14, 2018 in Las Vegas, NV.
A transcript of SmartTRAK’s interview with Scott Drees is below, or click the following video to view the interview recorded live at NANS 2018. (17:41 minutes.)
SmartTRAK is excited to be attending #ISC 2018 - International Stroke Conference, January 24-26 at the Los Angeles Convention Center.
The International Stroke Conference is the world’s premier meeting dedicated to the science and treatment of cerebrovascular disease.
SmartTRAK reports on two studies presented at INS 2017 evaluating the effect of VNS paired with rehab in stroke patients with upper limb paralysis.
One of the hottest emerging applications for neuromodulation is for improving function and movement in patients paralyzed by a stroke. Stroke affects almost 800,000 people every year in the US alone and is a leading cause of long-term disability, with an annual cost to the healthcare system of ~$33 billion.
At the International Neuromodulation Society (INS) 13th Annual Congress May 26-June 3 in Edinburgh, SmartTRAK interviewed Jesse Dawson, MD, Clinical Lead, Scottish Stroke Research Network, and Teresa Kimberley, PT, PhD Associate Professor, Division of Physical Therapy at the University of Minnesota, regarding a randomized, double-blinded trial evaluating the effect of vagal nerve stimulation (VNS) during stroke rehabilitation on upper limb function after an ischemic stroke using Microtransponder’s Vivistim System...
SmartTRAK will be at the International Neuromodulation Society 13th World Congress “Neuromodulation: Technology Changing Lives” in Edinburgh, Scotland May 27- June 1. Meet with Anne Staylor, Senior SmartTRAK Analyst and Managing Editor!
It’s been less than a year since Nuvectra Medical spun-off from Greatbatch Inc. (now Integer), and in that time Nuvectra has built a sales organization and laid the organizational foundation to become a, multi-indication neurostimulation company.
In an interview with BioMedGPS, Medtronic’s Marshall Stanton, MD discussed the Company’s strategies for gaining back market share in spinal cord stimulation and ongoing efforts to find the sweet spot in treating chronic intractable pain.